Telmisartan PKs of 48 health males with different genotypes.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05; **<i>P</i><0.01.</p><p>PKs, pharmacokinetics; <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

Summary of Genetic Variations of SNPs in this Study.

a<p>data published on hapmap; b, data calculated in this study, N = 48; N/A, no data found in hapmap.</p><p>MAF: Minor Allele frequencies; CHB: Han Chinese in Beijing, China; ASW: African ancestry in Southwest USA; CEU: Utah residents with Northern and Western European ancestry from the CEPH collection <i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; SNP, single nucleotide polymorphisms; AUC_(0–48) the area under the plasma concentration-time curve (AUC) from 0 to 48 h; AUC_(0–∞), AUC from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max.</p

The impacts of <i>ORM1</i> genotypes on the PKs and BP change(%) after 40 mg telmisartan.

<p>A, Concentration; B, AUC_(0–∞); C, SBP change(%) from the baseline; D, DBP change(%) from the baseline.</p

The demographics information of the participants.

<p>BMI, body mass index.</p

The P valve of variable factors on PK and BP change parameters in the corrected models.

<p>Data were shown as mean±SD;</p>*<p><i>P</i><0.05;</p>**<p><i>P</i><0.01.</p><p><i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; <i>ABCG2</i>, ATP-binding cassette, sub-family G, member 2; <i>ABCB1,</i> ATP-binding cassette, sub-family B, member 1; <i>SLCO1B3,</i> solute carrier organic anion transporter family, member 1B3; AUC_(0–∞) the area under the plasma concentration-time curve(AUC) from 0 to ∞; C_max, the peak concentration in plasma; CL/F, clearance; T_1/2, elimination half-life; T_max, the time to C_max; SBP, systolic blood pressure; DBP, diastolic blood pressure.</p

The impacts of <i>ABCC2</i> genotypes on the PKs and BP change(%) after 40 mg telmisartan.

<p>A, Concentration; B, AUC_(0–∞); C, SBP change(%) from the baseline; D, DBP change(%) from the baseline.</p

The significance affected by time or genotypes on the BP change(%) from the baseline.

*<p><i>P</i><0.05;</p><p><i>ORM1</i>, orosomucoid 1; <i>ABCC2</i>, ATP-binding cassette, sub-family C, member 2; SBP, systolic blood pressure; DBP, diastolic blood pressure; Time, the time point in this study including 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 48 h after taking telmisartan.</p